Northland Securities Reaffirms “Sell” Rating for DexCom (DXCM)

Northland Securities reaffirmed their sell rating on shares of DexCom (NASDAQ:DXCM) in a report published on Tuesday morning. The brokerage currently has a $40.00 target price on the medical device company’s stock.

A number of other brokerages also recently weighed in on DXCM. Barclays reaffirmed an equal weight rating and issued a $60.00 target price (down from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Citigroup downgraded shares of DexCom from an outperform rating to a market perform rating in a research note on Thursday, September 28th. BidaskClub raised shares of DexCom from a buy rating to a strong-buy rating in a research note on Tuesday, December 12th. Leerink Swann reaffirmed a buy rating and issued a $57.00 target price (down from $85.00) on shares of DexCom in a research note on Friday, September 29th. Finally, ValuEngine downgraded shares of DexCom from a hold rating to a sell rating in a research note on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $68.50.

Shares of DexCom (DXCM) traded down $0.23 during trading on Tuesday, hitting $56.05. 1,157,253 shares of the stock were exchanged, compared to its average volume of 1,978,369. DexCom has a 52-week low of $42.62 and a 52-week high of $86.32. The stock has a market capitalization of $4,870.00, a P/E ratio of -98.33 and a beta of 0.31. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. equities research analysts expect that DexCom will post -0.65 EPS for the current year.

In other DexCom news, insider Terrance H. Gregg sold 10,000 shares of DexCom stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total transaction of $568,600.00. Following the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold 48,140 shares of company stock worth $2,727,176 over the last three months. Insiders own 1.70% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Advisor Group Inc. grew its holdings in shares of DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares during the last quarter. Zions Bancorporation grew its holdings in shares of DexCom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after purchasing an additional 3,260 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of DexCom by 251.0% in the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after purchasing an additional 2,608 shares during the last quarter. CAPROCK Group Inc. bought a new position in shares of DexCom in the fourth quarter worth approximately $224,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of DexCom by 12.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after purchasing an additional 354 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “Northland Securities Reaffirms “Sell” Rating for DexCom (DXCM)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/19/northland-securities-reaffirms-sell-rating-for-dexcom-dxcm.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply